In the present study, Autodock 4.0 was employed to discover potential carbonic anhydrase IX inhibitors that are able to interfere with microtubule dynamics by binding to the Colchicine binding site of tubulin. Modifications at position 2¢ of estrone were made to include moieties that are known to improve the antimitotic activity of estradiol analogs. 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-3-ol-17-one estronem (C9) and 2-ethyl-3-Osulphamoyl-estra-1,3,5(10)16-tetraene (C12) were synthesized and tested in vitro. Growth studies were conducted utilizing spectrophotometrical analysis with crystal violet as DNA stain. Compounds C9 and C12 were cytotoxic in MCF-7 and MDA-MB-231 tumorigenic and metastatic breast cancer cells, SNO non-keratinizing squamous epithelium cancer cells and HeLa cells after 48 h exposure. Compounds C9 inhibited cell proliferation to 50% of the vehicle-treated controls from 110 to 160 nM and C12 at concentrations ranging from 180 to 220 nM. Confocal microscopy revealed abnormal spindle morphology in mitotic cells. Cell cycle analysis showed an increase in the number of cells in the G 2 /M fraction after 24 h and an increase in the number of cell in the sub-G 1 fraction after 48 h, indicating that the compounds are antimitotic and able to induce apoptosis.
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Key words: biological screening, mechanism-based drug design, virtual screening Received 30 April 2010, revised 15 November 2010 and accepted for publication 20 November 2010 Most of the chemotherapeutic anticancer drugs used in the clinic today include agents that target the cell cycle to inhibit the hyperproliferation of cancer cells and subsequently induce apoptosis (1) (2) (3) . Microtubule-interfering drugs bind to microtubules at diverse sites. Vinblastine binds at the plus end and inhibits microtubule polymerization (4) . Colchicine forms complexes between the a-and b-tubulin dimers to suppress microtubule dynamics, and Paclitaxel binds along the interior surface of the microtubule, thereby interfering with the dynamics of the microtubules (4) . Various agents that bind to the colchicine-binding site of microtubules are in various stages of clinical trials. These include combretastatins and its various analogs as well as 2-methoxyestradiol (2ME) (5, 6 ).
2-Methoxyestradiol is an endogenous metabolite of 17b-estradiol exerting both antiangiogenic and antimitogenic effects in vitro and in vivo (7) . Abrogation of microtubule dynamics is one of the mechanisms of action of 2ME, and it is proposed that 2ME interacts with the colchicine-binding site of microtubules (5, 8) . 2ME has short half-life and has been shown to be a target for 17b-hydroxysteroid dehydrogenase-mediated metabolism (9) . It is thus important to develop novel 2ME derivatives that are able to improve bioavailability and potency.
Sulfamates, including sulfamoylated derivatives of 2ME, have increased bioavailability because they are able to transit the liver without undergoing first pass metabolism (10) (11) (12) . This is attributed to the ability of sulfamoylated derivatives to reversibly bind to carbonic anhydrase II (CAII) in red blood cells after which they are then slowly released into the blood circulation system (10, 13) . Carbonic anhydrases are zinc enzymes that catalyze the conversion of carbon dioxide and water to carbonic acid (13) . Tumor cells have a lower extracellular pH than normal cells, and the acidotic environment promotes the action of growth factors and proteases involved in tumor progression (14) . Carbonic anhydrase IX (CAIX) is overexpressed in a variety of tumors and is implicated in the acidification of the extracellular environment of tumors (15, 16) . The CAIX gene contains a hypoxia-response element (HRE) that binds active HIF-1a and induces the transcription of CAIX (15) . The characteristic hypoxic microenvironment of tumors together with the HRE of the CAIX gene explains the overexpression of CAIX in a variety of tumors (15) . Selective inhibition of CAIX provides a valuable strategy for curtailing the development of metastatic processes associated with acidotic microenvironmental conditions in tumors. The aim of this study is to utilize non-commercial bioinformatics software to identify potential CAIX inhibitors that are capable of interfering with microtubule dynamics. After identifying the potential leads, a further aim was to synthesize the compounds and evaluate the effects of the newly synthesized compounds on cell growth, morphology, and cell division.
Materials and Methods

Materials
Heat-inactivated fetal calf serum (FCS), sterile cell culture flasks, and plates were obtained through Sterilab Services (Kempton Park, Johannesburg, South Africa). Dulbecco's minimum essential medium Eagle (D-MEM), penicillin, streptomycin, and fungizone were purchased from Highveld Biological (Pty) Ltd. (Sandringham, South Africa). A primary anti-tubulin alpha antibody from IMGENE (Alexandria, VA, USA) (cat no. IMG-80196) was purchased from BIOCOM biotech (Pty) Ltd. (Clubview, South Africa). The Alexa Fluor Ò 488, anti-mouse IgG H+L secondary antibody from Invitrogen (Carlsbad, CA, USA) (cat no. A21202), was purchased from The Scientific Group (Johannesburg, South Africa). All other chemicals were of analytical grade and were purchased from Sigma Chemical Co. (St. Louis, MO, USA).
Software
The Chimera package from the Resource for Biocomputing, Visualization, and Informatics at the University of California, San Francisco (supported by NIH P41 RR-01081), was used for structure preparation and visualization (17) . Reduce was used for adding hydrogens to the receptor Protein Data Bank molecular structure files (18) . Ligand conformational searches for X-ray ligands were made with VEGA 2.2.0 (19) . Docking studies were carried out with Autodock 4.0 and AutoDockTools4 (Scripps Research Institute, La Jolla, CA, USA) (20) . AutoDock4 evaluates the energies for both the bound and unbound states and uses a semi-empirical free energy force field by taking into account hydrogen bonding, electrostatic interactions, deviation from covalent geometry, internal ligand torsional constraints, and desolvation effects (20) . On average, a standard error of about 2-3 kcal ⁄ mol in prediction of binding free energy in cross-validation studies was found, and this was found to be good enough to differentiate between nm, lM, and mM activities of leads (20) . ACD ⁄ ChemSketch was used to generate Simplified Molecular Input Line Entry System (SMILES) annotations of ligands a . Threedimensional (3D) PDB atomic co-ordinates were generated from the SMILES annotations by the Online SMILES Translator b service provided by the computer-aided drug design (CADD) group and the National Cancer Institute (NCI). Protein structures for docking were gathered from the Research Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank.
Docking methodology
Human CAII is one of the most commonly studied enzymes with 279 X-ray crystallographic structures and a wealth of information regarding various inhibitors of CAII (21) . Tuccinardi et al. (2007) determined via cross-docking analysis using the ChemScore GOLD docking program that the 1OKN, 1KWR, 1CIM, 1BNW, 1CNX, 1OQ5, and 1TTM X-ray structures displayed the best root mean squared deviation (RMSD) average of the redocked ligands (22) . These receptors were chosen to be employed in the present study as part of an ensemble docking study (23) . Ligands extracted from 52 human CAII X-ray structures (Table S1 ) were redocked into the selected receptors, and the best score of each ligand was chosen. The correlation between the calculated Autodock 4.0 free energy of binding (AD4 € ) and the experimentally determined inhibition constant (expK i ) as well as the RMSD of the docked ligand compared to the X-ray structure was calculated. Genis et al. (2009) developed an effective mimic of CAIX for use in high-throughput screening of potential CAIX inhibitors (24) . The structures (3DC9, 3DCS, 3DCC, 3DC3, 3DCW, and 3DBU) generated from the study were included in the docking study. Five structures of tubulin were available (1SA0, 1SA1, 1Z2B, 3DU7, and 3E22) with two colchicine-binding sites each. Both were used for the ensemble docking to give a final total of 10 tubulin receptors. The Lamarckian genetic algorithm for conformational searching was used in Autodock with the ga_pop_-size and ga_num_evals parameters set to 250 and 2 500 000, respectively.
Receptor preparation
For receptor preparation, ligands, waters and other non-standard residue groups were removed. The water molecule between ASN62, ASN67, and GLN92 in the carbonic anhydrase receptors was included in docking simulations because they are present in most of the X-ray proteins analyzed (22) . Hydrogens were added by making use of the Reduce software. The software adds in a standardized geometry with optimization of the orientations of OH, SH, NH þ 3 , Met methyls, Asn and Gln side chain amides, and His rings (18) . After adding hydrogens, the Assisted Model Building with Energy Refinement (AMBER) Antechamber module (included with Chimera) was used to assign the Generalized AMBER force field types and atomic partial charges to each atomic residue of the PDB structure (25, 26) . After addition of hydrogens and atomic partial charges, the receptors were minimized utilizing the Amber ff99ua forcefield as implemented in Chimera (26, 27) . One thousand steps (step size of 0.02 Angstrom) of constrained minimization of the hydrogen network were followed by 500 steps (step size of 0.02 Angstrom) of side chain atoms to allow for internal hydrogen bond formation and removal of any internal clashes. After minimization, the respective tubulin, CAII and CAIX proteins were superimposed by the MatchMaker module in Chimera. The AD4_bound.dat parameters of Autodock 4.0 were used for receptor preparation and docking. Receptors were prepared with the prepare_receptor4.py script by adding Gasteiger charges and merging non-polar hydrogens. The zinc ion charge of carbonic anhydrase receptors was set to +2.
Ligand preparation
The ligands of 52 CAII-inhibitor complex structures from the RCSB Protein Data Bank were extracted (Table S1) . To generate a library of modified estradiol ligands, several modifications were made at positions 2 and the D-ring to generate a library of leads with potential antimitotic and anti-carbonic anhydrase activity (Table S2) . Position 3 was replaced with a sulfamate group. Modifications at position 2 were made to include moieties that are known to improve the antimitotic activity of estradiol analogs. Cushman et al. (1995) demonstrated that 2-(E)-1¢-propenyl and 2-ethoxy and substitutions improve the antimitotic activity of estradiol on several cancer cell lines (28) . Leese et al. (2004) demonstrated that a 2-methylsulphanyl substitution of estradiol greatly enhanced antiproliferative activity, while the 2-ethyl substitution enhanced antimitotic activity even more (11, 29) . Therefore, 2-methoxy, 2-ethoxy, 2-ethyl, 2-methylsulphanyl, and 2-(E)-1¢-propenyl derivatives were included in the lead library (Table S1 ). D-ring modifications that are known to improve the antiproliferative activity of estradiol analogs were also included. These include the 17-1¢-methylene substitution dis-covered by Edsall et al. (2004) (30) . Dehydration at positions 14 and 15 was shown to have increased antiproliferative and antitumor activities (31) . The 16-dehydrated antimitotic analog of 2ME (ENMD-1198) also shows promise and is currently undergoing clinical trials; therefore, dehydration at position 16 together with double dehydration at positions 14 and 16 was included in the library of lead ligands (32, 33) , and 17-O-sulphamate as well as 17-deoxy-17-cyano substitutions has also shown promise and was thus included in the docking study (34); 17-Hydroxy as well as 17-keto substitutions were also considered. All the modifications were made to generate a library of leads containing 85 ligands (Table S1 ).
Hydrogens were added to all ligands with VEGA. The ligands were subjected to a conformational search of 1000 steps in VEGA (19) . The systematic method with the SP4 forcefield and Another Molecular Mechanics Program -Maximum Overlap Method charges were used for the conformational search and minimization (20 steps, Toler = 0.01). Finally, the ligands were prepared for docking with AutoDockTools4 with the prepare_ligand4.py script. The charge of the zinc-binding nitrogen was changed to 0.800 (0.800 Acceptor 1 H-bond Nitrogen), and the charge of the hydrogen of the zinc-binding nitrogen was changed to )0.300 ()0.300 Donor 1 H-bond Hydrogen). This change improved docking conformations by constraining docking simulations to correctly form bonds between the sulfonamido nitrogen of the ligand and the zinc ion, as well as the hydrogen bond between the sulfonamido nitrogen's hydrogen and Thr199 in the docked conformations.
Chemistry
The synthesis of the lead compounds was outsourced to iThemba Pharmaceuticals (Pty) Ltd (Modderfontein, Gauteng, South Africa). All chemicals were purchased from Aldrich Chemical Co. (Milwaukee, WI, USA). Organic solvents of A.R. grade were used as supplied. Anhydrous N,N-dimethylformamide and N,N-dimethylacetamide were purchased from Aldrich and stored under a positive pressure of N 2 after use. Tetrahydrofuran was distilled from sodium. (35) . Chromatography was performed on silica gel (70-230 mesh; Macherey Nagel, Bethlehem, PA, USA). Thin layer chromatography was performed on Alugram Ò SIL G ⁄ UV 254 aluminum backed plates (Macherey Nagel). Products were visualized with basic potassium permanganate solution.
1 H NMR spectra were recorded in deuterated chloroform solution (unless otherwise indicated) with a Varian 400 NMR spectrometer at 400 MHz. Chemical shifts are reported in parts per million (ppm, d) relative to tetramethylsilane as an internal standard. Compounds were synthesized according to scheme 1 in Figure 1 and Table S1 . All the compounds were >90% pure and were analyzed by high-resolution mass spectrometry (Wits University, Johannesburg, South Africa) and NMR as described in Data S1 and Table S3 .
Cell culture MCF-7 (estrogen receptor positive) breast cancer cells, MDA-MB-231 (estrogen receptor negative) tumorigenic and metastatic breast cancer cells, esophageal cancer cell line non-keratinizing squamous epithelium cancer cells, and HeLa (human epithelial cervix carcinoma) cells were cultured in DMEM and supplemented with 10% heat-inactivated FCS (56°C, 30 min), 100 U ⁄ mL penicillin G, 100 lg ⁄ mL streptomycin, and fungizone (250 lg ⁄ L). The synthesized compounds were dissolved in dimethyl sulfoxide (DMSO) in different stock concentrations depending on the activity of each compound to allow the final concentration of DMSO not to reach levels greater than 0.05% in cell culture. Experiments were conducted in either 96-well plates or 6-well plates. For six-well plates, exponentially growing cells were seeded at 250 000 cells per well in 3 mL maintenance medium in 6-well plates on heat-sterilized coverslips. After 24-h incubation period at 37°C to allow for cell adherence, cells were exposed to the compounds including the vehicle control and incubated for 24 h at 37°C. For 96-well plates, exponentially growing cells were seeded at 5000 cells per well to a final volume of 200 lL of maintenance medium. After 24-h Figure 1 : Synthesis scheme of 2-ethyl estrone derivatives (Data S1). Docking, Synthesis, and in vitro Evaluation attachment, the medium was discarded, and the cells were exposed to the compounds including the vehicle control and incubated for 48 h at 37°C.
Crystal violet assay for determination of antiproliferative activity Quantification of fixated monolayer cells was spectrophotometrically determined employing crystal violet as a DNA stain. Staining cell nuclei of fixed cells with crystal violet allows for rapid, accurate, and reproducible quantification of cell number in cultures grown in 96-well plates (36, 37) . Dose-dependent studies were carried out to determine the growth inhibitory effect on the various cell lines of the newly synthesized compounds. The growth inhibitory effect was calculated as described by the National Cancer Institute to compare the growth inhibition induced by the compounds on the various cell lines (38) .
Confocal microscopy morphological observation of tubulin architecture Confocal microscopy was employed to observe the effects of the new compounds on the cytoskeletal microtubule architecture of control and treated MDA-MB-231 cells. Cells were fixated with glutaraldehyde and alpha-tubulin was immunostained with anti-alpha-tubulin antibodies c . Anti-alpha-tubulin antibodies were counterstained with an Alexa-488 fluorescent probe, and the nucleus was counterstained with 4¢,6-diamidino-2-phenylindole (DAPI). Stained cells were viewed with a Zeiss 510 META confocal laser microscope, and figures were generated with Zeiss' ZEN 2009 software (Carl Zeiss (Pty) Ltd., Johannesburg, South Africa).
Flow cytometric analysis of cell cycle progression Flow cytometry was employed to measure the DNA content of exposed and control cells to monitor the effect on cell cycle progression of MDA-MB-231 cells. Analysis was conducted by ethanol fixation and propidium iodide staining of cells. Propidium iodide was used to stain the nucleus to determine the amount of DNA present. Data from at least 10 000 cells were captured with CXP software [Beckman Coulter South Africa (Pty) Ltd, Johannesburg, Gauteng, South Africa] and analyzed with Cyflogic (CyFlo Ltd., Turku, Finland). Time-dependent studies were carried out at intervals of 24 and 48 h.
Results and Discussion
Docking results: reference ligands docked into CAII After docking the reference ligands of the CAII receptors, the AD4 € = 0.144 ln(exp K i ) ) 9.809 logarithmic function yielded a coefficient of determination (R 2 ) 0.5856 between exp K i and AD4 € (Figure 2) . The RMSD values ranged from 0.42 to 3.67 (Table S4 ). This result indicates that the docking software is able to at least differentiate between lM and nM active compounds.
Docking results: CAII versus CAIX
After docking the estrone analog ligands into the active sites of CAII and CAIX, it was observed that the 3-methoxy, 2-ethyl, and 2-methylsulphanyl moieties performed better than the other sterically larger moieties in both isoforms of CAs (Table S5) (Table S2 , test 50) had the best CAIX ⁄ CAII ratio of the compounds that have not been synthesized before (Table S5 ). Docking results: Tubulin colchicine-binding site After docking the ligands into the Colchicine-binding site between the alpha-and beta-dimers of the tubulin protein, it was revealed that the 2-ethyl derivatives performed better than all the other derivatives when compared to their corresponding D-ring-modified analogs (Table S6 ). This is in agreement with the results of Leese et al. (2006) , where it was discovered that an ethyl substitution at position 2 of estrone provided the optimal substituent for high antiproliferative activity (11) . The 2-ethyl ligands were docked within the hydrophobic pocket (ala180.A, ala250.B, leu242.B, leu248.B,  leu252.B, leu255.B, lys352.B, and val318.B) of the colchicine-binding site of tubulin (PDB id: 3E22). The sulfonamido nitrogen of the compounds is docked close to tyr202.B or the val238.B oxygen, allowing them to form possible hydrogen bonds (Figure 3) . Based on the docking results of the analogs into the colchicine site and the CAIX ⁄ CAII ratio of the compounds, it was decided to synthesize the novel 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10)16-tetraene and 2-ethyl-3-O-sulphamoyl-estra-1,3,5(10),15-tetraen-3-ol-17-one analogs. The 2-ethyl-17-(1¢-methylene)estra-1,3,5(10)-trien-3-O-sulphamate estrone analog also performed well; however, the synthesis of 2-ethyl-17-(1¢-methylene)estra-1,3,5(10)-trien-3-O-sulphamate was not completed for the present project and remains a possibility for future projects. The compounds are derivatives of estrone, and one concern is that these compounds might display estrogenic effects by binding to estrogen receptors and display agonist or antagonist activity. Cushman et al. (1995) synthesized several estradiol analogs, and it was discovered that modifications at C-2 position, including 2-methoxy, 2-ethoxy, 2-1-(E)-propenyl, 2-ethylthio, and 2-ethylamino, decreased the estrogenicity of the compounds (28). Purohit et al.
(1998) discovered that propyl and allyl groups at C-2 together with the sulfamate group greatly decrease the estrogenicity of the compounds to the levels comparable to propylene glycol (the vehicle control) (39) . The reason for this was ascribed to the bulking of the C-2 position of the estrones (39, 40) . Also, Elger et al. (2001) described how sulfamate substitution at C-3 leads to reduced estrogenic activity when compared to the parent steroids (41) . Thus, the ethyl group at C-2 together with the sulfamate group at C-3 of the newly synthesized analogs makes it unlikely that the compounds will have any estrogenic effects.
Antiproliferative activity of the compounds using crystal violet DNA stain assay The synthesized compounds were screened for antiproliferative activity using crystal violet as a DNA stain as described by Berry et al. (1996) (42) . The assay was carried out on MCF-7 breast cancer cells (estrogen receptor positive) tumorigenic and metastatic MDA-MB-231 breast cancer cells, non-tumorigenic MCF-12A breast cells, SNO non-keratinizing squamous epithelium cancer cells, and HeLa (human epithelial cervix carcinoma) cells. Compounds 9 and 12 reduced cell proliferation in a dose-dependent manner in all tested cell lines. The GI 50 concentrations for the compounds are summarized in Table 1 . In in vitro studies conducted in our laboratory, 2-ME showed an antiproliferative effect on HeLa, SNO, MCF-7, and MCF-12A cells in a concentration range of 1-2lM (43) (44) (45) . Accordingly, Edsall et al. (2004) demonstrated that the same compound inhibited MDA-MB-231 cancer cell proliferation by 50% at 1 lM (30). The present study revealed that compounds 9 and 12 are more potent than 2ME in vitro, showing nanomolar GI 50 values ( Table 1) . The GI 50 concentration of each compound was used in the subsequent studies on MDA-MB-231 cells because CAIX is overexpressed and associated with metabolic dysfunction in this cell line. Future mechanistic studies will include more cell lines (46). Confocal microscopy morphological observation of tubulin architecture Confocal microscopy was employed to observe the effects of compounds 9 and 12 on the cytoskeletal microtubule architecture of control and treated MDA-MB-231 cells after 24-h exposure. MDA-MB-231 vehicle-treated control cells presented with normal nuclear morphology and tubulin architecture during interphase, prophase, metaphase, anaphase, and telophase ( Figure 4 , Movie S1 and S2). Compounds 9 and 12 showed a similar type of interference with the mitotic spindle with abnormal formation of mitotic spindles (Figures 5 and 6 , Movie S3 and S4). These results confirm that the newly synthesized compounds are antimitotic agents that interfere with the microtubule dynamics in actively dividing cells.
Flow cytometric analysis of cell cycle progression DNA content of cells was measured as an indication of cells in the various stages of the cell cycle to determine the effect that compounds 9 and 12 have on cell cycle progression. An increase in the number of cells in the G 2 ⁄ M fraction was observed in both compounds 9-and 12-treated cells after 24 h when compared to the vehicle-treated control ( Figure 7) . Also, an increase in the sub-G 1 fraction was observed in both compounds 9-and 12-treated cells after 24 h, indicating an increase in apoptotic activity ( Figure 7) . After 48 h, the majority of the cells treated with compounds 9 and 12 were in the sub-G 1 fraction (Figure 8 ). These results indicate that the compounds are able to induce G 2 ⁄ M block after 24 h, and the cells in the G 2 ⁄ M block as a result of exposure to compounds 9 and 12 are more likely to enter apoptosis than remain in G 2 ⁄ M arrest or re-enter the cell cycle.
Conclusion and Future Directions
In the present study, docking studies were performed to assess the binding modes of estrone derivatives into CAII, CAIX, and the colchicine-binding site of tubulin. Based on the computational analysis, the compounds that performed the best in docking into the colchicine-binding site and had the best CAIX ⁄ CAII ratio were synthesized. Two new compounds with antimitotic activity in the sub-lM range were synthesized. The compounds are able to interfere with microtubule dynamics, resulting in a mitotic block and causes a subsequent increase in the sub-G 1 fraction which might indicate an increase in apoptotic or necrotic or both types of cell death. Future studies will focus on the binding mode of the compounds into the CAIX enzyme. With additional cellular-mechanistic studies, these compounds could lead to new candidates for the future development of antimitotic drugs that specifically target metastatic processes associated with acidotic microenvironmental conditions in tumors as a result of CAIX overexpression.
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